PureTech Receives FDA Fast Track Designation for LYT-200 in Acute Myeloid Leukemia (AML)

Jan 9

Written By Allison Talbot

Allison Talbot

PureTech’s Founded Entity Gallop Oncology to Present New Data from Ongoing Phase 1b Trial of LYT-200 in Relapsed/Refractory Acute Myeloid Leukemia (AML) at the American Society of Hematology (ASH)

PureTech Receives FDA Fast Track Designation for LYT-200 in Head and Neck Cancers